FDA Escalates Enforcement Against GLP-1 Telehealth Compounders (2025-2026)

What the letters allege

The FDA has cited misleading direct-to-consumer advertising, including claims that imply compounded products are FDA-approved or are "the same as" Zepbound. Several letters also documented sterility, labeling, and adverse-event-reporting deficiencies at specific facilities. A February 6, 2026 press release summarized the agency’s intent to act against non-FDA-approved GLP-1 products and their advertising, signaling the shortage-era enforcement-discretion window had closed and would not reopen absent a new statutory pathway.

The salt-form issue features heavily too. Warning letters cited tirzepatide and semaglutide salt forms (such as acetate) as unapproved active ingredients, reinforcing that only the base peptide is acceptable for compounding. For providers, that meant re-verifying the exact active ingredient their pharmacy used and updating any marketing language that overstated equivalence to brand products.

Enforcement actions at a glance

The escalation, visualized

Why the shift from discretion to enforcement

During the shortage, the FDA exercised enforcement discretion so patients would not lose access. When supply was declared resolved, that rationale disappeared, and the agency moved to close the gap between what the law allows and what a large compounding-and-telehealth market had built. The warning letters are the visible edge of that shift: they put operators on notice and build a record the FDA can rely on for stronger action if violations continue.

What a compliant provider looks like now

The providers least exposed to enforcement share a pattern: a genuine clinical evaluation before prescribing, a clearly disclosed pharmacy pathway, honest language that never implies FDA approval for compounded products, and increasingly an offer of FDA-approved options alongside any compounded route. If a provider cannot explain how it sources medication and documents medical necessity, treat that as a warning sign. Certification such as LegitScript is one useful signal, but it does not replace these fundamentals.

What it means for patients

Enforcement risk sits with providers, but it affects supply reliability and trust. Favor providers transparent about sourcing that either use documented 503A patient-specific compounding or prescribe FDA-approved products. Our provider-selection guide and April 2026 FDA action explainer walk through the checks. If a product or an offer seems off, pause and confirm with a licensed clinician or pharmacist before proceeding.

The salt-form dimension, in depth

A recurring thread across the enforcement wave is the active-ingredient question. The FDA has been explicit that only the base peptide forms of semaglutide and tirzepatide are acceptable, and that salt forms such as acetate are unapproved active ingredients. For patients, this is a concrete thing to verify: ask your pharmacy or provider to confirm the exact active ingredient used, and be wary of any program that cannot answer plainly. A provider that switched sourcing to base-form API and updated its marketing language accordingly is demonstrating exactly the kind of compliance the agency is now demanding, whereas silence or vague reassurance is a reason for extra scrutiny.

Frequently asked questions

Why is the FDA sending warning letters?

It says many mass-marketed compounded GLP-1s were sold with misleading claims and without a valid basis after the shortage ended. Letters cite advertising, sterility, labeling, and reporting issues.

Does a warning letter mean a product is dangerous?

Not automatically, but it signals the FDA found violations — a strong reason to verify a provider's pharmacy pathway and prefer FDA-approved options where possible.

Are legitimate telehealth providers affected?

Providers relying on large-scale compounding are most exposed. Those using documented 503A compounding or prescribing FDA-approved products are on firmer ground.

How can I check a provider?

Confirm the pharmacy pathway (503A vs 503B), look for independent certification such as LegitScript, and ensure a licensed clinician evaluates you before prescribing.